TY - JOUR
T1 - Accurate classification of secondary progression in multiple sclerosis using a decision tree
AU - The BeAMS study group
AU - Ramanujam, Ryan
AU - Zhu, Feng
AU - Fink, Katharina
AU - Karrenbauer, Virginija Danylaitė
AU - Lorscheider, Johannes
AU - Benkert, Pascal
AU - Kingwell, Elaine
AU - Tremlett, Helen
AU - Hillert, Jan
AU - Manouchehrinia, Ali
AU - Shirani, A.
AU - Zhao, Y.
AU - Evans, C.
AU - van der Kop, M. L.
AU - Gustafson, G.
AU - Petkau, J.
AU - Oger, J.
N1 - Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: R.R., P.B., and F.Z. have nothing to disclose. A.M. was supported by the Margaretha af Ugglas Foundation. K.F. received an unrestricted research grant from Biogen, NeuroFonden, and Neuroföbundet. K.F. has received travel compensation for lectures for Novartis, Biogen, TEVA, Almirall, and Merck. V.K. received financial support from Stockholm County Council and Biogen’s Multiple Sclerosis Registries Research Fellowship Program. V.K. has also received an unrestricted grant from Biogen and a project grant from Novartis. J.H. received honoraria for serving on advisory boards for Biogen and Genzyme and speaker’s fees from Biogen, Novartis, Teva, and Sanofi-Genzyme. He has served as P.I. for projects sponsored by, or received unrestricted research support from, Biogen, Sanofi-Genzyme, and Novartis. His multiple sclerosis research is funded by the Swedish Research Council and the Swedish Brain Foundation. H.T. is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis. Current research support was received from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada, and the Multiple Sclerosis Scientific Research Foundation. In addition, in the last 5 years, she has received research support from the UK MS Trust; travel expenses to present at CME conferences from the Consortium of MS Centers (2018), the National MS Society (2016 and 2018), European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)/Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) (2015, 2016, 2017, 2018, 2019, and 2020), and American Academy of Neurology (2015, 2016, and 2019). Speaker honoraria are either declined or donated to an MS charity or to an unrestricted grant for use by H.T.’s research group. E.K. was supported through research grants from the Canadian Institutes of Health Research and the Multiple Sclerosis Society of Canada. In addition, during the last five years, she has received travel expenses to give presentations, or attend CME conferences, from ACTRIMS, ECTRIMS, and the MS Society of Canada. J.L. received research support from Innosuisse—Swiss Innovation Agency, research grants from Biogen and Novartis and honoraria for serving on advisory boards from Roche and Teva.
Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Swedish Strategic Research Foundation, by the Swedish Brain Foundation, and by the Swedish Research Council. The BeAMS Study group was funded by the Canadian Institutes of Health Research (CIHR) [MOP-93646] and the US National MS Society [#RG 4202-A-2].
Funding Information:
The authors wish to thank neurologists, nurses, and multiple sclerosis patients in Sweden and Canada, as well as the Swedish Multiple Sclerosis Register for providing data for this study. We gratefully acknowledge the BC MS Clinic neurologists who contributed to the study through patient examination and data collection (current members at the time of data extraction listed here by primary clinic): UBC MS Clinic: A Traboulsee, MD, FRCPC (UBC Hospital MS Clinic Director and Head of the UBC MS Programs); A-L Sayao, MD, FRCPC; V Devonshire, MD, FRCPC; S Hashimoto, MD, FRCPC (UBC and Victoria MS Clinics); J Hooge, MD, FRCPC (UBC and Prince George MS Clinic); L Kastrukoff, MD, FRCPC (UBC and Prince George MS Clinic); and J Oger, MD, FRCPC; Kelowna MS Clinic: D Adams, MD, FRCPC; D Craig, MD, FRCPC; and S Meckling, MD, FRCPC; Prince George MS Clinic: L Daly, MD, FRCPC; Victoria MS Clinic: O Hrebicek, MD, FRCPC; D Parton, MD, FRCPC; and K Atwell-Pope, MD, FRCPC. The views expressed in this paper do not necessarily reflect the views of each individual acknowledged. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Swedish Strategic Research Foundation, by the Swedish Brain Foundation, and by the Swedish Research Council. The BeAMS Study group was funded by the Canadian Institutes of Health Research (CIHR) [MOP-93646] and the US National MS Society [#RG 4202-A-2].
Publisher Copyright:
© The Author(s), 2020.
PY - 2021/7
Y1 - 2021/7
N2 - Background: The absence of reliable imaging or biological markers of phenotype transition in multiple sclerosis (MS) makes assignment of current phenotype status difficult. Objective: The authors sought to determine whether clinical information can be used to accurately assign current disease phenotypes. Methods: Data from the clinical visits of 14,387 MS patients in Sweden were collected. Classifying algorithms based on several demographic and clinical factors were examined. Results obtained from the best classifier when predicting neurologist recorded disease classification were replicated in an independent cohort from British Columbia and were compared to a previously published algorithm and clinical judgment of three neurologists. Results: A decision tree (the classifier) containing only most recently available expanded disability scale status score and age obtained 89.3% (95% confidence intervals (CIs): 88.8–89.8) classification accuracy, defined as concordance with the latest reported status. Validation in the independent cohort resulted in 82.0% (95% CI: 81.0–83.1) accuracy. A previously published classification algorithm with slight modifications achieved 77.8% (95% CI: 77.1–78.4) accuracy. With complete patient history of 100 patients, three neurologists obtained 84.3% accuracy compared with 85% for the classifier using the same data. Conclusion: The classifier can be used to standardize definitions of disease phenotype across different cohorts. Clinically, this model could assist neurologists by providing additional information.
AB - Background: The absence of reliable imaging or biological markers of phenotype transition in multiple sclerosis (MS) makes assignment of current phenotype status difficult. Objective: The authors sought to determine whether clinical information can be used to accurately assign current disease phenotypes. Methods: Data from the clinical visits of 14,387 MS patients in Sweden were collected. Classifying algorithms based on several demographic and clinical factors were examined. Results obtained from the best classifier when predicting neurologist recorded disease classification were replicated in an independent cohort from British Columbia and were compared to a previously published algorithm and clinical judgment of three neurologists. Results: A decision tree (the classifier) containing only most recently available expanded disability scale status score and age obtained 89.3% (95% confidence intervals (CIs): 88.8–89.8) classification accuracy, defined as concordance with the latest reported status. Validation in the independent cohort resulted in 82.0% (95% CI: 81.0–83.1) accuracy. A previously published classification algorithm with slight modifications achieved 77.8% (95% CI: 77.1–78.4) accuracy. With complete patient history of 100 patients, three neurologists obtained 84.3% accuracy compared with 85% for the classifier using the same data. Conclusion: The classifier can be used to standardize definitions of disease phenotype across different cohorts. Clinically, this model could assist neurologists by providing additional information.
KW - Multiple sclerosis
KW - classification
KW - decision tree
KW - secondary progressive
UR - http://www.scopus.com/inward/record.url?scp=85097041917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097041917&partnerID=8YFLogxK
U2 - 10.1177/1352458520975323
DO - 10.1177/1352458520975323
M3 - Article
C2 - 33263261
AN - SCOPUS:85097041917
SN - 1352-4585
VL - 27
SP - 1240
EP - 1249
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 8
ER -